Aquaculture Acquisition to Create Vaccine Innovation Powerhouse
KoVax’s research and development team has joined Phibro’s biological R&D team, and will focus on developing a pipeline of innovative vaccines for the aquaculture market. Phibro’s first commercial aquaculture vaccine is KoVax’s “KV3” vaccine, which helps prevent Koi Herpes Virus, a highly contagious disease that can cause significant mortality in common carp farms.
Commenting on the acquisition, Phibro’s Vice President of Aquaculture, Dr.
Dr. Ariav added, “Phibro Aqua is on the move with the launch of several successful nutritional products in the past year and a major investment to build up our technical support team. We are now well-positioned to deliver outstanding products and unmatched support services to our global aquaculture customers, and we have no intention of slowing down.”
Chief Financial Officer
Source: Phibro Animal Health Corporation